Physician profile
Ahra Cho
NPI 1902051659
$9,444.54
in general payments reported to CMS, 2019-2025
41 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $1,002 · 2021: $2,482 · 2022: $1,745 · 2023: $1,346 · 2024: $1,098 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,771.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,205.02 | 2019-2025 | Linzess, Viberzi |
| Amgen INC. | $1,110.09 | 2019-2025 | Repatha, Evenity, Repatha |
| Lilly USA, LLC | $739.08 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Ibsa Pharma INC. | $627.99 | 2021-2023 | Tirosint, Licart |
| Novo Nordisk INC | $569.77 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals LP | $559.93 | 2020-2025 | Farxiga, Airsupra |
| Nestle Healthcare Nutrition INC. | $478.56 | 2020-2022 | |
| Amarin Pharma, INC. | $416.81 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $402.29 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $357.77 | 2020-2024 | Linzess |
| Sumitomo Pharma America, INC. | $267.57 | 2023-2025 | Gemtesa |
| Aimmune Therapeutics, INC. | $252.72 | 2024-2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.82 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.58 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.84 | 2022-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $179.91 | 2021-2022 | |
| Stryker Corporation | $169.91 | 2025 | Augment Injectable |
| Lundbeck LLC | $151.39 | 2023-2025 | Rexulti |
| Celltrion, INC. | $144.60 | 2020 | |
| Scilex Pharmaceuticals INC. | $128.69 | 2021-2024 | Ztlido |
| Pfizer INC. | $113.31 | 2019-2023 | |
| Esperion Therapeutics, INC. | $99.71 | 2021 | |
| Vivus LLC | $83.43 | 2023-2025 | Pancreaze |
| Dexcom, INC. | $79.47 | 2022-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $64.19 | 2022-2025 | Arexvy, Shingrix |
| Eisai INC. | $62.35 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $54.66 | 2024-2025 | Voquezna |
| Biogen, INC. | $49.51 | 2024-2025 | Leqembi |
| Astellas Pharma US INC | $48.84 | 2021-2022 | |
| Exact Sciences Corporation | $48.73 | 2023-2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $47.16 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $31.52 | 2024-2025 | Rexulti |
| Dentsply Sirona INC | $29.40 | 2023 | Suresmile |
| Abbott Laboratories | $28.35 | 2025 | Eterna |
| Merck Sharp & Dohme LLC | $28.32 | 2023 | Belsomra |
| Insmed, INC. | $24.99 | 2025 | Brinsupri, Arikayce |
| Biohaven Pharmaceutical Holding Company LTD. | $24.56 | 2022 | |
| Shield Therapeutics INC | $23.31 | 2025 | |
| Almatica Pharma LLC | $21.86 | 2025 | Loreev Xr |
| Allergan, INC. | $19.79 | 2020 | |
| Smith+Nephew, INC. | $19.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahra Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.